1. Patient‐reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer. Issue 5 (12th November 2013) Authors: Welslau, Manfred; Diéras, Veronique; Sohn, Joo‐Hyuk; Hurvitz, Sara A.; Lalla, Deepa; Fang, Liang; Althaus, Betsy; Guardino, Ellie; Miles, David Journal: Cancer Issue: Volume 120:Issue 5(2014) Page Start: 642 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Patient‐reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer. Issue 5 (12th November 2013) Authors: Welslau, Manfred; Diéras, Veronique; Sohn, Joo‐Hyuk; Hurvitz, Sara A.; Lalla, Deepa; Fang, Liang; Althaus, Betsy; Guardino, Ellie; Miles, David Journal: Cancer Issue: Volume 120:Issue 5(2014) Page Start: 642 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. Issue 1 (December 2016) Authors: Krop, Ian; Modi, Shanu; LoRusso, Patricia; Pegram, Mark; Guardino, Ellie; Althaus, Betsy; Lu, Dan; Strasak, Alexander; Elias, Anthony Journal: Breast cancer research Issue: Volume 18:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗